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Recent clinical research has shown that atorvastatin (ATO) in combination with cholesterol
absorption inhibitor ezetimibe (EZE) signiﬁcantly reduces LDL-C level in patients with
hypercholesterolemia, showing a superior lipid-lowering efﬁcacy compared to statin
alone. With no information currently available on the interaction between the two drugs, a
pharmacokinetic study was conducted to investigate the inﬂuence of EZE on ATO and
conversely when the two drugs were coadministered. The purpose of this study was
to investigate the presence of differences in the pharmacokinetic proﬁles of capsules
containing ATO 80 mg, EZE 10 mg or the combination of both 80/10 mg administered to
healthy Mexican volunteers.This was a randomized, three-period, six-sequences crossover
study. 36 eligible subjects aged between 20 to 50 years were included. Blood samples
were collected up to 96 h after dosing, and pharmacokinetic parameters were obtained by
non-compartmental analysis. Adverse events were evaluated based on subject interviews
and physical examinations. Area under the concentration-time curve (AUC) and maximum
plasma drug concentration (Cmax) were measured for each drug alone or together and
tested for bioequivalence-based hypothesis. The estimation computed (90% conﬁdence
intervals) for AUC and Cmax, were 96.04% (85.88–107.42%) and 97.04% (82.36–114.35%),
respectively for ATO–EZE combination versus ATO alone, while 84.42% (77.19–92.32%)
and 95.60% (82.43–110.88%), respectively, for ATO–EZE combination versus EZE alone
were estimated.These results suggest that ATO and EZE have no relevant pharmacokinetic
drug–drug interaction.
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INTRODUCTION
Atorvastatin (ATO) is a member of a lipid-lowering family
of agents called statins, is a synthetic reversible inhibitor of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase;
the rate-limiting enzyme in cholesterol biosynthesis (Liu et al.,
2010). This HMG-CoA reductase inhibitor can efﬁciently and
dose dependently lower both cholesterol (25–61%) and triglyc-
eride (9–61%) levels in hyperlipidemic patients, (Nawrocki et al.,
1995; Heinonen et al., 1996) and produces a signiﬁcantly larger
reduction (38–51%; P ≤ 0.01) of colesterol and triglycerides com-
pared with the equivalent doses of other statin drugs (Jones et al.,
1998). Following oral administration, ATO is rapidly absorbed,
and maximum plasma concentrations are achieved within 1–
2 h. ATO is extensively metabolized by cytochrome P450 3A4 to
active metabolites: ortho- and parahydroxy ATO. Approximately
70% of the circulating inhibitory activity for HMG-CoA reduc-
tase is attributed to these active metabolites (Pﬁzer Inc. Lipitor®,
2009). Although the pharmacokinetics or bioavailability of ATO
has been previously studied in other populations (Posvar et al.,
1996; Koytchev et al., 2004; Bahrami et al., 2005; Liu et al., 2010),
a few studies were reported in Mexican subjects.
Ezetimibe (EZE) is the ﬁrst of the cholesterol absorption
inhibitors, a novel class of lipid modifying drugs, which potently
inhibit the absorption of biliary and dietary cholesterol from the
small intestine without affecting the absorption of fat-soluble vita-
mins, triglycerides or bile acids (van Heek et al., 2000). Following
oral administration EZE is readily absorbed and glucuronidated
(EZE-G) in the intestinal epithelium, that is pharmacologically
active phenolic glucuronide. EZE-G enters an enterohepatic recir-
culation reaching dual peak blood levels at 4–6 and 10–12 h,
suggesting enterohepatic recirculation of EZE and conjugated
form (van Heek et al., 2000; Patrick et al., 2002; Malloy and Kane,
2007; Mahley and Bersot, 2008). The drug and its metabolite are
eliminated slowly; with terminal elimination half-life of 20–30 h
(Ezzet et al., 2001). EZE is used as monotherapy or in combination
with statins for the reduction of elevated levels of TC, LDL-C, and
Apo B in patients with primary hypercholesterolaemia (Mahley
and Bersot, 2008). EZE had no effect on the activity of major
drug metabolizing enzymes (CYP450), which reduces any poten-
tial drug–drug interactions with other medications (van Heek and
Davis, 2002).
The possibility of combining cholesterol-lowering medications
to attain greater LDL-C lowering is therefore an important thera-
peutic option for more effective intervention on cardiovascular
risk reduction for high–and very high–risk patients. One cur-
rently available approach is the simultaneous intervention by two
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complementary mechanisms regulating plasma colesterol levels:
intestinal cholesterol absorption and hepatic cholesterol synthe-
sis (Ballantyne et al., 2005). The combined use of ATO–EZE
and the study of non-interaction between the two formulations
is an interesting alternative for the treatment of patients with
hypercholesterolemia and cardiovascular disease risk.
On the other hand, several analytical methods exist for analysis
of ATO (Bahrami et al., 2005; Bhatt et al., 2010), and EZE (Sistla
et al., 2005; Li et al., 2006; Bahrami et al., 2010). In accordance
to Draft Guidance published for Food and Drug Administration’s
(FDA’s), the Schuirmann hypothesis is based in ATO in human
plasma, and the ATO metabolites only provide complementary
information about metabolism of drug in the organism (Row-
land and Tozer, 2011). For the EZE the Draft Guidance (FDA’s)
considers only the total EZE quantiﬁed in human plasma.
Therefore, the aim of the present study was to investigate
the presence of differences in the pharmacokinetics proﬁles of
a ﬁxed-dose formulation alone and in combination of ATO
(80 mg) and EZE (10 mg) in oral dose in healthy fasted Mex-
ican volunteers, using a bioequivalence-based hypothesis to
perform a non-interaction analysis between the two assessed
drugs.
MATERIALS AND METHODS
STUDY DESIGN AND PROCEDURES
The study was a randomized, open-label, crossover type Williams
(1949), prospective longitudinal a single dosage not therapeu-
tic of 80 mg of ATO (Treatment A), 10 mg of EZE (Treatment
B) or a combination of both (Treatment AB), trial in healthy
Mexican subjects under fasting condition. Thirty six healthy
Mexicans volunteers of both gender who were between the
ages of 18 and 45 (mean ± SEM: 24.71 ± 0.03 years), had
heights between 140.0 and 190.0 cm (163.0 ± 0.005 cm), and
weighed between 43.50 and 79.50 kg (62.15 ± 1.9 kg) were
enrolled in the study. The study protocol was approved by
an independent ethics committee as well as by the regulatory
authority in Mexico (COFEPRIS), and it was conducted fol-
lowing the ethical principles described in the Declaration of
Helsinki.
Subjects received formulations in three separate sessions
according to the scheme shown in the Table 1, with 14 day
washout between sessions. The demographic characteristics of the
volunteers are presented in Table 1.
BLOOD SAMPLING
Blood samples (4 mL) were collected from a suitable forearm vein
by an indwelling catheter or by immediate venipuncture at the fol-
lowing time points: 0.0 (before administration), 0.25, 0.50, 0.75,
1.0, 1.5, 2.0, 2.25, 2.50, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 12.0, 24.0, 48.0,
72.0, and 96.0 h after study drug administration. Prior to each
sample collection, 1 mL of blood was drawn and discarded. After
sampling, the catheter was ﬂushed with 0.8 mL of sodium hep-
arin (25 IU/mL) to ensure patency. Blood samples were drawn
into pre-labeled heparin containing tubes and plasma samples
were separated within 30 min after drawing by centrifugation at
3000 rpm for 10 min at room temperature. Plasma was stored
frozen (≤–20◦C) in labeled polypropylene tubes until analysis.
MATERIALS AND REAGENTS
Analytical standards of calcium ATO and IS (paroxetine), EZE
and IS (hydrochlorothiazide) were kindly donated by a phar-
maceutical company (Laboratorios SENOSIAIN, S. A. de C. V.).
β-glucuronidase from Helix pomatia (Sigma-Aldrich, USA), ace-
tonitrile MS grade (EMD Chemicals, USA) and ammonium
formiate HPLC grade (Fluka, USA) were acquired with local dis-
tributors. All working solutions in this study were prepared with
deionized water.
DRUG FORMULATIONS
The test and reference formulation was manufactured by Labora-
torios SENOSIAIN, S. A. de C. V. (Mexico). A formulation of ATO
capsules (40 mg), EZE capsules (10 mg), and ATO–EZE capsules
(40 mg/10 mg) were used in the pharmacokinetic study available
in batches with valid certiﬁcates of analysis and were kept in a
sealed container at a controlled room temperature of 15–25◦C
until further use.
QUANTIFICATION OF PLASMA CONCENTRATIONS OF ATO AND TOTAL
EZE BY LC-MS/MS METHOD
For the determination of both molecules were developed an ana-
lytical method, where only once plasma processing is used to
obtain both molecules, but the quantiﬁcation of the analytes was
performed on two separate injections ATO in positive electro-
spray ionization ESI (+) mode and EZE in negative electrospray
ionization ESI (−) mode. The calibration curve used to deter-
mination of ATO was in the range 1–60 ng/mL, the paroxetine
(10 μg/mL) was used as internal standard, the range used to EZE
is 0.5–100 ng/mL, and the hydrochlorothiazide (10 μg/mL) was
used as internal standard.
SAMPLE PREPARATION
Frozen plasma samples were thawed at room temperature. A
0.3 mL aliquot of human plasma was spiked with each stock
solution (5 μL of ATO and 5 μL of EZE) of calibration curve
samples and quality control samples, and IS (5 μL of paroxetine
and 5 μL of hydrochlorothiazide) solution. Then, 0.5 mL sodium
acetate buffer 0.025 M pH 5.0 was added. Ten microliters of
β-glucuronidase from Helix pomatia (>90000 UI/mL) was added,
the mixture was vortexed for 0.5 min. The mixture was incubated
at 40 ± 3◦C from 1 h. After incubation the reaction was ﬁnished
with 100 μL of NaOH 0.1N. One mL of ethyl acetate was added to
extract analytes, the mixture was vortexed for 1.0 min. After mix-
ing, the samples were frozen for 5 min at −80◦C, after centrifuged
for 5 min at 14,000 rpm with a bench-top centrifugal separa-
tor (Eppendorf 5418, Germany). A total volume of the organic
extract was evaporated to dryness under a stream of nitrogen and
reconstituted in 300 μL of acetonitrile:water (50:50). The total
volume was transferred to a glass autosampler vial and a 2.0 μL
aliquot of the solution was injected into the LC-MS/MS system for
analysis.
LC-MS/MS AND CONDITIONS
Chromatographic analysis was performed on UPLC-MS/MS sys-
tem consisting of Acquity UPLC coupled to a tandem mass
spectrometry detector XEVO-TQS (Waters, USA) and Acquity
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Table 1 | Demographic characteristics and formulation sequence of administration of the healthy Mexican volunteers.
Volunteer Sex Age (y) Height (cm) Weight (kg) BMI (%) Sequence (period)
I II III
1 Male 24 162 62 23 AB B A
2 Female 29 156 55 22 AB B A
3 Male 18 168 60 21 A AB B
4 Male 24 182 78 23 AB A B
5 Female 26 170 60 20 AB A B
6 Male 44 171 67 22 A B AB
7 Female 37 162 70 26 A AB B
8 Male 34 164 67 24 AB B A
9 Male 24 172 66 22 A AB B
10 Male 43 173 71 23 A B AB
11 Female 33 172 63 21 A B AB
12 Male 23 166 56 20 B AB A
13 Male 32 178 83 26 A AB B
14 Female 25 156 50 20 B A AB
15 Male 24 167 62 22 AB A B
16 Male 37 165 73 26 AB B A
17 Male 24 171 74 25 B A AB
18 Female 34 155 62 25 A B AB
19 Male 27 183 78 23 AB A B
20 Male 25 167 71 25 B AB A
21 Male 26 166 60 21 B A AB
22 Female 20 166 59 21 A AB B
23 Female 19 168 60 21 A AB B
24 Male 32 159 67 26 B A AB
25 Male 49 150 53 23 A B AB
26 Male 26 172 75 25 AB B A
27 Male 21 185 76 22 B AB A
28 Female 32 168 68 24 AB B A
29 Male 18 183 67 20 B AB A
30 Male 27 165 61 22 B A AB
31 Male 46 167 65 23 A B AB
32 Male 21 169 67 23 B AB A
33 Female 29 143 45 22 B AB A
34 Male 30 172 67 22 B A AB
35 Female 21 162 57 21 AB A B
36 Female 25 150 55 24 AB A B
Tablets containing 80 mg Atorvastatin (A), Ezetimibe 10 mg (B), Atorvastatin/Ezetimibe 80/10 mg respectively (AB). BMI, body mass index.
UPLC BEH C18 (1.7 μm, 2.1 × 100 mm) column (Waters, USA).
The mobile phase consisted of an acetonitrile-5 mM ammo-
nium formiate buffer solution (80:20, v/v) at 0.2 mL/min ﬂow
rate. The run time was 2.6 min; the sample volume injected was
2.0μL. The column temperature was set to 40◦C. The autosampler
cooler was set at 8◦C. For ATO the mass spectrometer was set in
multiple reactions monitoring (MRM) mode in ESI positive ion-
ization mode. Collision energy and cone voltage were 12 and 19V,
respectively. Cone and desolvation gas ﬂow rate were set to 150
and 600 L/min, respectively, using Argon as collision gas at ﬂow
rate of 0.15 mL/min. Tandem mass spectrometer was tuned to
monitor m/z 559.25 → m/z 440.30 transition for ATO and m/z
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330.10 → m/z 192.20 transition for the IS (paroxetine), with dwell
timeof 0.3 s. For EZE themass spectrometerwas set inMRMmode
in ESI negative ionization mode. Collision energy and cone volt-
age were 12 and 15V, respectively. Tandem mass spectrometer was
tuned to monitor m/z 408.15 → m/z 271.20 transition for EZE
and m/z 296.0 → m/z 269.00 transition for the IS (hydrochloroth-
iazide), with dwell time of 0.2 s. MRM data were acquired and
analyzed through MassLynx software (Waters, USA).
ASSAY VALIDATION
The analytical method was validated according to criteria estab-
lished by the Mexican Regulatory Guidelines (NOM-177-SSA1-
1998, 2013). Drug-free plasma was spiked with ATO and EZE
solution to obtain a calibration curve. In the same manner, QC
samples (points) were prepared at low,medium, and high concen-
tration levels (6.0, 24.0, and 52 ng/mL for ATO and 5.0, 50.0, and
90ng/mL forEZE),and thesewere employed todetermine absolute
recovery and intra- and interday precision and accuracy. Selectiv-
ity was evaluated by preparing the lower limit of quantitation
(LLOQ) in lipemic or hemolyzed plasma and by spiking drug-free
plasma with ciproﬂoxacin, paracetamol, difenidol, ranitidine, and
caffeine. Stability [biological matrix at –70◦C, bench-top at room
temperature (20◦C), three freeze-and-thaw cycles, enzymatic reac-
tion at 40◦C for 1 h, andprocessed samples inside the autosampler]
was also evaluated.
PHARMACOKINETIC ANALYSIS
Pharmacokinetic parameters for ATO and EZE were calculated
using non-compartmental and compartmental models with Win-
Nonlin 6.2.1 software (Pharsight,MountainView,CA,USA,2011).
From the individual data, it was estimated the pharmacokinetic
parameters of ATO and EZE. The Maximum plasma concentra-
tion (Cmax), time to reach Cmax (Tmax), area under the plasma
concentration-time curve (AUC) from time 0 to the time of
the last measurable concentration (AUC0−t) and AUC extrap-
olation to inﬁnity (AUC0−∞) was calculated according to the
non-compartmental method. For estimation of the absorption
rate constant (Ka), half-life of the absorption process (T1/2 abs) as
well as the disposition and elimination parameters: apparent vol-
ume of distribution (V/F), clearance apparent (CL/F), elimination
rate constant (Ke), and elimination half-life (T1/2), the best model
that described the individual pharmacokinetic data was ﬁtted as
an open model of one compartment with ﬁrst order absorption
without lag-time.
STATISTICAL ANALYSIS
In accordance with the Mexican Regulatory Guidelines
(NOM-177-SSA1-1998, 2013), 36 volunteers were the minimum
sample required (assuming an 80% power to detect a 20% dif-
ference). An ANOVA for a 3 × 6 crossover design was performed
on the decimal logarithm-transformed parameters Cmax,AUC0−t ,
and AUC0−∞ to evaluate ﬁxed effects such as period, sequence,
formulation, and carryover. Logarithm-transformed values of
these parameters were considered to construct a classic CI at 90%,
with P < 0.05 indicating signiﬁcance. The formulations were con-
sidered bioequivalent if the 90% CI of the logarithm-transformed
ratios (test/reference) of Cmax (an index of the rate of absorp-
tion), AUC0−t , and AUC0−∞ (indexes of extent of absorption)
were within the predeﬁned range of 0.80–1.25.
RESULTS
ANALYTICAL METHOD
We measure the total concentration of EZE, after incubation of
plasma samples in the presence of β-glucuronidase enzyme. Thus,
after enzymatic treatment of the plasma levels of total EZE and
ATO were quantiﬁed with a method of Ultraperformance Liquid
Chromatography coupled to mass spectrometry, using an ana-
lytical method developed and validated, through a technique of
liquid-liquid extraction. The biological samples were analyzed by
liquid chromatography with separate injections for each analyte
(ATO and EZE) and validated according to the Mexican Guide-
line (NOM-177-SSA1-1998, 2013). The method was selective,
robust and satisﬁes the stability requirements evaluated during
validation.
PHARMACOKINETIC PROFILES
The data was analyzed under the null hypothesis of interaction
(bioequivalence-based hypothesis), we expect the average time
courses by period suggest an increase or reduction of signiﬁcant
magnitude at the levels reached by the drug when administered in
combination compared to when administered alone. The poten-
tial pharmacokinetic interactions should be explained not only in
terms of magnitude, also with the factor that explains the differ-
ence to propose the type and magnitude of the implication that
such interaction would have on the effectiveness and drugs safety
(Hauschke et al., 2007; Zhang et al., 2009).
In Figures 1A and 2A the average time courses in arith-
metic scale, the plasma concentration of ATO and EZE are
comparatively shown in each of the periods in which vol-
unteers received the drug reference (ATO or EZE alone) or
test drug (ATO–EZE). From Figure 1A shows that on average,
the time proﬁles of ATO plasma concentrations were similar
between the reference formulation and test. With both for-
mulations Cmax values reached 11–13 ng/mL which reached
around 1.5–2.5 h, which is better appreciated in Figure 1C
(0–12 h). When the course ATO pharmacokinetic proﬁle was
analyzed on a logarithmic scale (Figure 1B) were found that
curves generated for both products (test and reference) over-
lapped.
For EZE, in Figures 2A,B the time courses of the plasma in
both logarithmic and arithmetic scale as shown. In both cases, it
can be seen that the average peak concentration EZE is higher and
reaches a little faster when given alone compared to when given
in combination with ATO (Figure 2C). However, from the second
hour no differences in drug levels between formulations, including
the double peak that appears between the 4 and 6 h, corresponding
to enterohepatic recirculation of EZE (Kosoglou et al., 2005)which
is very similar between test and reference products.
PHARMACOKINETIC PARAMETERS
Through the non-compartmental estimation of pharmacokinetic
parameters (Table 2) showed that the average maximum con-
centration (±SD) of ATO in formulating Test (combination
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FIGURE 1 |Time-course of plasma levels of atorvastatin (80 mg) when given alone or in combination with 10 mg of ezetimibe in healthy subjects.
(A) Arithmetic proﬁle 0–25 h; (B) Semilogarithmic proﬁle 0–25 h; (C) Arithmetic proﬁle 0–12 h.
ATO–EZE) is slightly higher (19.80 ± 14.52 ng/mL) that produced
only when the drug is given: ATO (18.78 ± 8.89 ng/mL), but is
achieved at a similar time (Tmax: 2.03 ± 1.31 h) compared to that
observed with the reference formulation (Tmax: 2.08 ± 1.41 h).
The above results are in agreementwith the reported for Lennernäs
(2003), which states that after doses of 20 and 40 mg of ATO Cmax
of 6.9 is reached at 12.7 ng/mL 1–2 h. In the case of values of
AUC0−t 76.79 ± 44.47 ng × h/mL and 76.01 ± 36.09 ng × h/mL;
while the AUC0−inf were 89.08 ± 48.97 ng × h/mL and
87.42 ± 40.47 ng × h/mL for the test formulations (ATO–EZE
combination) and reference (ATO) respectively. In this regard,
results of other authors describes that after 80 mg dose AUC0−t
reached is of the order of 102–134 ng × h/mL (Jacobson, 2004).
In order to compare the process of elimination of ATO after
administration of both products, the following values for the elim-
ination half-life were estimated: 4.23 ± 2.17 h for the combination
ATO–EZE3.97± 2.03h andwhen thedrugwas administered alone
(ATO).
Furthermore, when comparing the individual results, regard-
ing the ATO–EZE combination in this study, it was conﬁrmed
that reported by the manufacturer of the ﬁrst product registered
for the combination (Zhu et al., 2001; Kosoglou et al., 2002;
Zetia, 2014), there seems to be a clinically relevant pharma-
cokinetic interaction. Furthermore, in the case of EZE, the
Cmax of the drug in the subjects treated with the combina-
tion ATO–EZE (21.09 ± 8.57 ng/mL) were 17.3% lower on
average than that produced when the drug is administered
alone: EZE (24.76 ± 10.27 ng/mL) and was reached at a
longer period [Tmax: 2.33 ± 1.46 h with respect to the refer-
ence formulation (EZE) 1.33 ± 1.20 h]. The bioavailability of
EZE measured by AUC0−t showed that the combination with
385.83 ± 186.36 ng × h/mL are reached values very simi-
lar to the drug alone (386.82 ± 175.37 ng × h/mL). While,
AUC0−inf was 432.57 ± 206.49 and 454.25 ± 200.01 ng × h/mL
for the test formulations (ATO–EZE combination) and ref-
erence (EZE) respectively. In clear correspondence with pre-
vious results, bioavailability was observed that the half-life
of the terminal elimination phase was 22.88 ± 12.61 h for
ATO–EZE and 23.58 ± 12.14 h for the reference product:
EZE. These results led to the proposition that there must be
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FIGURE 2 |Time-course of plasma levels of ezetimibe (10 mg) when given alone or in combination with 80 mg of atorvastatin in healthy subjects.
(A) Arithmetic proﬁle 0–96 h; (B) Semilogarithmic proﬁle 0–96 h; (C) Arithmetic proﬁle 0–12 h.
Table 2 | Statistical evaluation of non-interaction for Atorvastatin bioavailability parameters in volunteers who received administration of the
formulations evaluated: A: Atorvastatin 80 mg;AB [fixed dose combination (80 mgAtorvastatin/Ezetimibe 10 mg)].
A vs. AB (n = 36)
Formulation A
reference
Formulation B
test
Ratio B/A
%
Westlake
interval 90%
Clasic interval
90%
Unilateral double test Schuirmann
(p < 80; p > 120 p total)
Ln Cmax 2.82 2.79 97.04 83.53 82.36 0.0273 0.0067
0.09 0.09 116.47 114.35 0.0340
Ln AUC0−t 4.23 4.19 96.04 87.66 85.88 0.0046 0.0002
0.08 0.08 112.34 107.42 0.0048
Ln AUC0− inf 4.37 4.36 98.21 88.81 87.91 0.0018 0.0004
0.08 0.08 111.19 109.71 0.0022
Cmax, Maximum concentration; AUC0−t, area under curve to the ﬁnal observation; AUC0− inf, area under curve extrapolated to inﬁnity.
some pharmacokinetic interaction in the absorption process
for EZE. Kosoglou et al. (2002) reported that the parent drug
is rapidly absorbed and is biotransformed into glucuronide
active metabolite (>80%), and reaches the maximum levels
between 1 and 2 h post-administration, involved a enterohep-
atic recirculation and slow elimination. However, the levels of
EZE shown by the author to the dose of 10 mg are generally
higher than those achieved in the present study, in particular
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mentioned that the Cmax is 64.2–73.6 ng/mL, which is reached
between 1.2 and 2.3 h, while the area under the curve to the end
point 440–722 ng × h/mL.
DISCUSSION
Due to the clinical study design, we use statistical approach based
on the Schuirmann hypothesis (bioequivalence-based hypothe-
sis) using pharmacokinetic parameters of drugs. The compliance
with this hypothesis demonstrated that no pharmacokinetic drug
interaction occurred in the present combination.
In order to establish the approval of the hypothesis (non-
interaction), intervals classic symmetrical Westlake (90%) conﬁ-
dence were calculated, and the unilateral double test Schuirmann
was applied to the logarithmic transformation of the Cmax param-
eters AUC0−t , AUC0−inf of ATO and EZE in the evaluated
formulations. Corresponding analyzes were performed using the
program WinNonlin (WinNonlin 6.2.1, 2011).
The results of Table 2 show there is no difference between
the single administrations of ATO with respect to when given in
combination with EZE, means no pharmacokinetic interaction.
However, in the case of parameter Cmax is close to the estab-
lished acceptance criteria (≥0.8). In this regard, ATO is a molecule
has shown an intra-subject variability >30%. The Lipitor drug,
shows a high intra-individual variability according to diverse reg-
ulatory bodies such as the European Medicines Agency [EMEA]
(2010), in this sense, is accurate to extend the acceptance crite-
ria of the conﬁdence interval at 90% for Cmax parameter values
between 0.75 and 1.33. Under this consideration is re-analyzed
the data and conﬁrmed that using the expansion of the range for
the parameter Cmax power, in this pharmacokinetic parameter,
is >0.8 criterion established regulatory acceptance, which would
lead to establish that using this strategy statistical analysis, one
can conclude that the presence of EZE does not produce an inter-
action on the pharmacokinetics of ATO. The chemical nature of
ATO and the mechanism of action of EZE are probably the rea-
sons behind this ﬁnding, because EZE inhibits the absorption of
biliary and dietary cholesterol, but apparently it does not have the
ability to inhibit the absorption of ATO, even though the polarity
of the molecule of ATO is low (Drugbank, 2014). Furthermore
there is not an increase in the bioavailability or a change in the
elimination rate, so this suggests that EZE does not have any effect
in the pharmacokinetic proﬁle of ATO at the administered doses.
For EZE the Table 3 shows that for the Cmax parameter (log-
transformed), the ratio test: reference has an average value of
84.42%, means that not exceeded the expectation of ±20%,
considered conventional as the observed differences translate
into relevant clinically implication (Hauschke et al., 2007). How-
ever, the estimation of the conﬁdence interval as both Westlake
Classic 90%, as well as double-sided Schuirmann test suggests
that the test product does not meet the criteria (80–125%). In
contrast, the assessment of the areas under the curve shows
that both the ratio test: reference (95.60 and 91.17%) as tests
and conﬁdence intervals Schuirmann meet or are close to the
level of compliance to consider the approval of the hypothesis.
However, it is important to clarify that this is not a bioe-
quivalence study, but analysis consist in a bioequivalence-based
hypothesis to analyze the potential pharmacokinetic interac-
tion between the components of the combination ATO–EZE
(80/10 mg).
Although it is reported that EZE, has not signiﬁcant inter-
actions in plasma levels in combination with statins (Kosoglou
et al., 2002) in our study we found at least an increase in the
Cmax level of EZE (10 mg) when administered with 80 mg of
ATO. Nevertheless, this ﬁnding could be relevant based on a
previous analysis of pharmacodynamic parameters in a popu-
lation (Kakara et al., 2014) which suggests in a simulation that
Rosuvastatin when combined with EZE have a superior clini-
cal response due to a decrease in the LDL synthesis. In fact,
the beneﬁcial effects of this combination (ATO–EZE) have been
studied at preclinical (Van Rooyen et al., 2013) and clinical level
(Bennett et al., 2004; Okada et al., 2012).
On the other hand, the possible mechanism to explain the
change in the Cmax of EZE when administered with ATO is
unknown and this study was not designed to answer this situa-
tion. However, the difference could be induce by an alternative
mechanism of action of ATO that clearly affects the bioavailabil-
ity and not to the elimination rate, because the AUC’s measures
remain with no changes.
Table 3 | Statistical evaluation of non-interaction for the parameters of bioavailability of Ezetimibe in volunteers who received administration
of the formulations evaluated: B: Ezetimibe 10 mg;AB [fixed dose combination (80 mgAtorvastatin/Ezetimibe 10 mg)].
B vs. AB (n = 36)
Formulation A
reference
Formulation B
test
Ratio B/A
%
Westlake
interval 90%
Classic interval
90%
Unilateral double test Schuirmann
(p < 80; p > 120 p total)
Ln Cmax 3.14 2.97 84.42 78.78 77.19 0.1585 0.0000
0.07 0.07 121.22 92.32 0.1585
Ln AUC0−t 5.86 5.82 95.60 84.37 82.43 0.0250 0.0022
0.07 0.07 115.63 110.88 0.0271
Ln AUC0− inf 5.90 5.84 93.91 83.62 81.28 0.0345 0.0010
0.07 0.07 116.38 108.50 0.0355
Cmax , Maximum concentration; AUC0−t, area under curve to the ﬁnal observation; AUC0− inf , area under curve extrapolated to inﬁnity.
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CONCLUSION
No evidence of interaction was found, in the pharmacokinetic
process toATO (80mg) produced by the co-administration of EZE
(10 mg), however, if small differences in Cmax EZE (10 mg) were
documented after the co-administration of 80 mg of ATO, which
are not sufﬁcient to conclude that ATO is capable of producing
a reduction in the absorption of EZE, especially that the areas
under the curve (overall drug exposure) no showing difference
according to the strategy statistics employed bioequivalence-based
hypothesis (Schuirmann hypothesis).
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